IN-VITRO ACTIVITY OF TROVAFLOXACIN, A NEW FLUOROQUINOLONE, AGAINST RECENT CLINICAL ISOLATES

Trovafloxacin (CP-99,219) was very active against Gram-negative specie s examined including Haemophilus influenzae, Moraxella catarrhalis, Le gionella spp., Neisseria spp. and Escherichia coli (MIC(90)s less than or equal to 0.03 mg/L). In general trovafloxacin was twice as active as ofloxacin but only half as active as ciprofloxacin against Gram-neg ative species. Trovafloxacin was active against Gram-positive organism s, including Staphylococcus aureus, Streptococcus pneumoniae, Streptoc occus pyogenes and Enterococcus faecalis (MIC(90)s less than or equal to 0.25 mg/L). Against these organisms activity was eight to 16 times greater for trovafloxacin than for either ofloxacin or ciprofloxacin. In addition, Chlamydia spp., Mycoplasma spp. and Ureaplasma urealyticu m were eight to 16 times more susceptible to trovafloxacin than to eit her ofloxacin or ciprofloxacin. These in-vitro data show that trovaflo xacin is a broad-spectrum fluoroquinolone with greater activity agains t clinically important Gram-positive species compared with ofloxacin o r ciprofloxacin.